Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle

Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc PFE and BioNTech SE BNTX to be used in EU countries' vaccination campaigns this autumn to combat yet another Covid-19 variant. But although this virus hasn’t disappeared, cancer still remains one of the biggest health challenges of our lifetime, and a battle that the pharmaceutical industry is far from winning.

Pfizer Promises To Battle Cancer At The Speed of science

In mid-August, The U.S. Food and Drug Administration therapy approved a blood cancer therapy that Pfizer developed. Branded as Elrexfio, Pfizer developed a therapy to empower the body's immune system kill cancerous cells by bringing a cancer cell and an immune cell together. Regulators have allowed the use of this therapy in patients with multiple myeloma that is hard to treat and to those who suffered from recurrence of the disease. 

Moderna Is Poised To Unlock New Cancer Treatment

At the end of July, Moderna Inc MRNA and Merck MRK began a late-stage study of skin-cancer combination treatment that includes a personalized mRNA-based skin cancer vaccine along with the immunotherapy Keytruda. The mid-stage study conducted in 157 melanoma patients revealed that the vaccine combination lowered the risk of recurrence or death by 44% in comparison to treatment with Keytruda alone. The vaccine is tailored for each patient to activate the key player of the body's immune response, T-cells, based on the tumor’s specific mutational signature. BioNTech SE BNTX and Gritstone Bio Inc GRTS are also are also developing cancer vaccines based on the mRNA technology. Scientists have been trying to develop these vaccines for decades without success but this combination of mRNA vaccines with immune boosting drugs promise to create a new generation of cancer therapies. 

Yet, There’s Little Talk Of Cancer Prevention And Early Detection.

Yet, unlike the COVID-19 scenario, there’s still little talk about prevention or at the very least, early detection of cancer. Today, a molecular genetics diagnostic company specializing in the early detection of life-threatening conditions, Mainz Biomed N.V. MYNZ, announced a strategic partnership with Ärztliches Labor Dr. Buhlmann in attempt to strengthen its market positioning. Its flagship product, ColoAlert®, is positioned as an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. Already marketed across Europe, it is undergoing a pivotal FDA clinical study for US regulatory approval. The company is also developing PancAlert, an early-stage screening test for pancreatic cancer.

A Massive Opportunity Ahead For Mainz Biomed

In 2022, The Association of Substitute Health Insurance Funds in 2022 estimated that approximately 10.5% of Germany’s population, which is about 8.7 million individuals, are covered by private health insurance (PHI) and a substantial portion of these beneficiaries are within the critical 50-74 age range, which is the targeted demographic for CRC screening. Moreover, CRC is the third most common cancer in the world, according to the World Cancer Research Fund International. The market opportunity in the U.S. is massive as roughly one-third of the country’s population aged 50-75 have never been screened for colon cancer, translating to more than $4 billion market opportunity for Mainz Biomed. 

Mainz Biomed Is Poised To Expand Its Footprint Across The Globe

With its latest strategic partnership with Ärztliches Labor Dr. Buhlmann, a respected player in PCR-based analysis, Mainz Biomed gained the opportunity to further expand into Germany’s private health insurance arena where its ColoAlert® is already eligible for reimbursement. But, this partnership also promises to fuel its vision of facilitating early CRC detection across the globe as besides her public and private sector networks, Dr. Buhlmann’s laboratory will bring considerable expertise in pioneering molecular diagnostic tests to this promising company. Dr. Buhlmann also acknowledged the company’s innovative contribution to dramatically improving CRC testing.

Covid Or No Covid, Pharma Has Yet To Win Its Biggest Battle

The Covid-19 virus hasn’t disappeared, but so haven’t many life-threatening diseases which is why innovative companies that focus on prevention of life-threatening diseases and on early detection that has the power to prevent the development of the diseases and a lethal outcome, such as Mainz Biomed, deserve all the support they can get.

DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.